NCT02420366View on ClinicalTrials.gov

Study of Cases of Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae

CompletedOBSERVATIONAL

Enrollment

257

Participants

Timeline

Start Date

May 31, 2014

Primary Completion Date

January 31, 2015

Study Completion Date

January 31, 2015

Conditions

Urinary Tract Infection, ComplicatedAcute PyelonephritisHospital Acquired Bacterial PneumoniaVentilator-associated Bacterial PneumoniaBacteremia

Trial Locations (22)

161

Rome

168

Roma

10032

New York

10065

New York

14642

Rochester

15261

Pittsburgh

16132

Genova

22908

Charlottesville

27710

Durham

33100

Udine

40138

Bologna

44195

Cleveland

48201

Detroit

50134

Florence

56124

Pisa

60201

Evanston

60611

Chicago

08901

New Brunswick

08244

Somers Point

11527 Goudi

Athens

M239LT

Manchester

MI39WL

Manchester

All Listed Sponsors

lead

Rempex (a wholly owned subsidiary of Melinta Therapeutics, Inc.)

INDUSTRY

NCT02420366 - Study of Cases of Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae | Biotech Hunter | Biotech Hunter